Buján J, Jurado F, Gianonatti C, Contreras L A
Department of Morphological Sciences and Surgery, Faculty of Medicine, University of Alcalá de Henares, Madrid, Spain.
Histol Histopathol. 1994 Jul;9(3):433-42.
Cyclosporine-A (CsA) is a potent immunosuppressor used successfully to control rejection in organ transplantation. According to the most recent evidence, this drug modifies the lipid metabolism of the patient, provoking a rise in the blood lipids, constituting an important risk factor for acceleration of the atherogenic process. Taking into account that brown adipose tissue (BAT) constitutes the major storage site for cholesterol and triglycerides in the rat, and given the apparent lack of references about the implications of CsA on this tissue in the literature, we proposed to study the possible morphological changes occurring in BAT following the administration of this drug. Two groups of female Sprague-Dawley rats were set up, the control group and a treated group in which each animal received subcutaneous injection of 5 mg/kg body weight/day of CsA. After 4, 11, 25 and 34 days of treatment, subgroups of animals were sacrificed and the brown adipose tissue removed was apportioned for subsequent microscopic assessment. The greatest degree of atypia and activity in the BAT was observed after administration of 11 doses of the drug, at which point there was a marked reduction in the cell size with loss of lipidic coalescence. With subsequent doses, the tissue slowly initiated a process of recovery. CsA also induced morphological changes in the BAT that, in the early stages of the study, appeared to be correlated with a lipolytic response of the tissue to the drug; thus, the BAT may be acting as a system to eliminate the excess of lipids in the blood provoked by CsA administration, while toward the end of treatment, there was a certain stability between the drug and the activity of the brown adipose tissue, and a tendency to reach a balance between lipolysis and lipogenesis.
环孢素A(CsA)是一种强效免疫抑制剂,已成功用于控制器官移植中的排斥反应。根据最新证据,这种药物会改变患者的脂质代谢,导致血脂升高,成为加速动脉粥样硬化进程的重要危险因素。鉴于棕色脂肪组织(BAT)是大鼠体内胆固醇和甘油三酯的主要储存部位,且文献中明显缺乏关于CsA对该组织影响的参考文献,我们提议研究给予这种药物后BAT可能发生的形态学变化。设立了两组雌性斯普拉格-道利大鼠,即对照组和治疗组,治疗组中的每只动物皮下注射5mg/kg体重/天的CsA。在治疗4、11、25和34天后,处死动物亚组并取出棕色脂肪组织,分配用于后续显微镜评估。在给予11剂药物后,观察到BAT中出现了最大程度的异型性和活性,此时细胞大小明显减小,脂质融合丧失。随着后续给药,组织开始缓慢恢复。CsA还诱导了BAT的形态学变化,在研究早期,这些变化似乎与组织对药物的脂解反应相关;因此,BAT可能作为一个系统来消除CsA给药引起的血液中过量脂质,而在治疗末期,药物与棕色脂肪组织的活性之间存在一定的稳定性,并且有在脂解和脂肪生成之间达到平衡的趋势。